Abstract
Among the main pathological evidence affecting Parkinson's disease (PD) patients is the death of dopaminergic neurons of the substantia nigra pars compacta. Dopamine replacement can be done with L-3,4-dihydroxyphenylalanine (L-DOPA) but chronic use of this drug is associated with the onset of motor complications known as L-DOPA-induced dyskinesias (LIDs). Inhibition of the phosphodiestera…